期刊
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
卷 18, 期 2, 页码 259-272出版社
SPRINGER
DOI: 10.1007/s11154-017-9417-0
关键词
Vitamin D; Cardiovascular; Mortality; Vitamin D receptor; Epidemiology; Cardiovascular risk; Review
资金
- Amgen Switzerland AG
- Synlab Holding Deutschland Germany
- GmbH
- AMGEN
- BASF
- Sanofi
- Siemens Diagnostics
- Aegerion Pharmaceuticals
- Astrazeneca
- Danone Research
- Numares
- Pfizer
- Hoffmann LaRoche
- MSD, Alexion
- Abbott Diagnostics
Vitamin D has long been established as an elemental factor of bone physiology. Beyond mineral metabolism, the expression of the vitamin D receptor has been identified throughout the cardiovascular (CV) system. Experimental studies showed beneficial effects of vitamin D on heart and vessels, but vitamin D intoxication in animals also led to hypercalcemia and vascular calcification. Our knowledge has been extended by epidemiological studies that showed that 25-hydroxyvitamin D (25(OH)D) levels are inversely associated with an increased CV risk itself, but also with established CV risk factors, such as arterial hypertension, endothelial dysfunction and atherosclerosis. Conversely, randomized controlled trials could not document significant and consistent effects of vitamin D supplementation on CV risk or events. Potential explanations may lie in differences in reference ranges or the possibility that low vitamin D in CV disease is only an epiphenomenon. In the latter case, the key question is why low 25(OH)D levels are such a strong predictor of health. While we wait for new data, the current conclusion is that vitamin D is a strong risk marker for CV risk factors and for CV diseases itself.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据